Brenda Goodman, MA
News
Second U.S. COVID-19 case caused by Omicron found
December 2, 2021
“This news is concerning, but it is not a surprise.”
![1]()
News
FDA panel backs first pill for COVID-19 by a small margin
November 30, 2021
If authorized by the agency, molnupiravir would be first antiviral agent available as a pill to treat COVID-19.
News
Merck’s COVID-19 pill may be less effective than first hoped
November 30, 2021
The new results seem to put molnupiravir far below the effectiveness of existing treatments.
![1]()
News
FDA authorizes Pfizer’s COVID-19 vaccine for kids
October 29, 2021
As soon as the CDC’s director signs off on those recommendations, children can get the shots, perhaps as early as Nov. 3.
News
FDA panel votes to approve Pfizer’s vaccine for children
October 26, 2021
If the FDA follows the recommendation, as it typically does, ...the shots could be available within days.
![1]()
News
FDA authorizes boosters for Moderna, J&J, allows mix-and-match
October 20, 2021
The move gives the vaccine experts on the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices latitude to recommended a mix-and-match strategy, if they feel the science supports it.
![1]()
News
FDA panel backs second dose for Johnson & Johnson vaccine recipients
October 15, 2021
It will be up to a Centers for Disease Control and Prevention (CDC) panel to make more specific recommendations for who might need another shot.
![1]()
News
FDA advisors vote to recommend Moderna boosters
October 14, 2021
The panel voted to authorize a 50 milligram dose — half the dose used in the primary series of shots — to boost immunity against COVID-19 at least 6 month after the second dose.
News
CDC chief overrules panel, OKs boosters for health care workers
September 24, 2021
Panelists “did not buy the need in occupational or institutional settings.”
![1]()
News
FDA OKs Pfizer COVID booster for 65 and over, those at high risk
September 23, 2021
Emerging evidence shows that booster doses of the Pfizer vaccine cause front-line immune defenders — called binding antibodies — to roughly triple soon after a person gets the third shot.
